Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK141 in KRAS G12D Mutant Advanced Solid Tumors
NCT07417189Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABSK141 in solid tumor, sponsored by Abbisko Therapeutics. Started Mar 2026; status: recruiting.
02
Drugs
ABSK141
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07417189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07417189.